US Patent

US9545405 — Pyrrolo[2,3-D]pyrimidine derivatives

Composition of Matter · Assigned to Pfizer Inc · Expires 2034-02-19 · 8y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects pyrrolo[2,3-D]pyrimidine derivatives, which are used as Janus Kinase (JAK) inhibitors and are contained in pharmaceutical compositions.

USPTO Abstract

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.

Drugs covered by this patent

Patent Metadata

Patent number
US9545405
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-02-19
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.